GenNext Technologies and Agilent have combined their proprietary technologies to optimise the research protocols of biopharma companies worldwide.
The two companies have integrated the AutoFox Protein Footprinting System and Agilent's 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) LC/MS System.
This will allow biopharmaceutical researchers to analyse a protein structure in detail, as well as facilitating biomolecule interaction studies.
The aim of the technological integration for both companies is to offer researchers more comprehensive insights on their studies, while also helping scientists make high-value decisions on which candidates to progress.
The workflow starts with Hydroxyl Radical Protein Footprinting (HRPF) by GenNext's system, followed by detection and quantification on the Agilent IM-QTOF system.
GenNext's FoxWare and Agilent's MassHunter IM-MS softwares then perform data analysis.
AutoFox
GenNext's Protein Footprinting system incorporates FoxWare software, and has been designed to deliver high-resolution protein footprinting data.
This technology allows researchers to better understand the structures of subject proteins, while also mapping any confirmational changes that may occur during testing.
The system can map protein-ligand interactions, therapeutic-target interactions and protein conformations in their native environments.
6560 IM-QTOF LC/MS
Agilent's system specialises in advanced ion mobility separation, while also utilising high-resolution mass spectrometry.
This allows for the analysis of complex biological samples, as it can separate ions based on their shape and charge.
From this, more structural information can be obtained from a protein sample, facilitating its comprehensive analysis.
"We are thrilled about the possibilities the Agilent collaboration opens up for structural biology research," said Scot Weinberger, CEO of GenNext Technologies. "The integration of our two powerful technologies offers researchers a state-of-the-art toolset for advancing their understanding of protein structures and interactions."
"Agilent is committed to pushing the boundaries of scientific discovery," added Jennifer Gushue, Associate Vice President of LC/MS Marketing at Agilent. "Our IM-QTOF system, combined with GenNext's innovative protein footprinting technology, will provide researchers with the critical insights needed to drive the next generation of biopharmaceutical advancements."
